Jan Leschly: This One Didn't Clear The NetJulia Flynn
Jan Leschly is on the defensive. Following the acrimonious Feb. 23 collapse of merger talks between SmithKline Beecham and Glaxo Wellcome, Leschly, a tennis pro turned SmithKline CEO, is under pressure from investors to get a deal.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.